Wednesday, February 28, 2018 5:27:25 AM
in the last reverse split, the stock fell from $13 to $1, then surged to $2.25. It was definitely going to go on a multi-day run, or sure felt like it, and then they announce the convertible loan.
On the day they announce the end to the convertibles, it shoots up from 4 cents to past 9 cents -- and again we are on the cusp of a multi-day run. Then we just get hammered with more dilution.
After this past awful financing, the stock mostly held up. I was starting to almost regret selling most of my shares at the market open. And then, they announce plans for more financing, a higher AS, and a future RS. If the meeting is in April, did they need to announce it so soon?
It feels like the company has a real focus of making sure this stock punishes people right now. I mostly babble away on another thread right now, on a "scam" stock I no longer own, but that scam stock at least has a mgmt which tries to pump the stock and raise the PPS.
Here, if and when this stock gets good news about Chemostat, etc, they'll give us the good news in piss from a bad liver. Which is inappropriate for a company if it doesn't despise its shareholders.
On the day they announce the end to the convertibles, it shoots up from 4 cents to past 9 cents -- and again we are on the cusp of a multi-day run. Then we just get hammered with more dilution.
After this past awful financing, the stock mostly held up. I was starting to almost regret selling most of my shares at the market open. And then, they announce plans for more financing, a higher AS, and a future RS. If the meeting is in April, did they need to announce it so soon?
It feels like the company has a real focus of making sure this stock punishes people right now. I mostly babble away on another thread right now, on a "scam" stock I no longer own, but that scam stock at least has a mgmt which tries to pump the stock and raise the PPS.
Here, if and when this stock gets good news about Chemostat, etc, they'll give us the good news in piss from a bad liver. Which is inappropriate for a company if it doesn't despise its shareholders.
Recent DCTH News
- Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts • Business Wire • 05/26/2026 08:01:00 PM
- Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/15/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:47:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 12:23:52 PM
- Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference • Business Wire • 05/12/2026 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 01:09:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 12:12:12 PM
- Delcath Systems Reports First Quarter 2026 Results and Business Highlights • Business Wire • 05/07/2026 12:00:00 PM
- Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026 • Business Wire • 05/07/2026 11:00:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/27/2026 08:12:24 PM
- Delcath Systems to Host First Quarter 2026 Earnings Call • Business Wire • 04/23/2026 12:30:00 PM
- Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma • Business Wire • 04/06/2026 12:30:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/02/2026 12:56:15 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/02/2026 12:55:31 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/02/2026 12:52:52 PM
- Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting • Business Wire • 04/01/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:22:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:48:16 PM
- Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology • Business Wire • 03/03/2026 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 02:15:35 PM
